Thyrocare Technologies Limited is an Indian multinational chain of diagnostic and preventive care laboratories, headquartered in Navi Mumbai.

[1] As of 2021, the company has a total of 1,122 outlets and collection centers across India and parts of Nepal, Bangladesh and the Middle East.

[10] In 2010, Thyrocare raised its first private equity funding of ₹188 crore from New Delhi-based CX Partners in exchange for a 30% stake.

[15] In April 2016, Thyrocare made its initial public offering (IPO),[16] and became the second diagnostic firm in India to be listed on BSE and NSE.

[22] In July 2020, a Thyrocare lab in Pune was banned from conducting Covid-19 tests after producing false positive reports.